Alefacept is safe and efficacious in the treatment of palmar plantar pustulosis

Journal of Cutaneous Medicine and Surgery

Volumn 11, Issue 6, 2007, Pages 202-205

  Guenther, Lyn C ^a  

^a Guenther Dermatology Research Centre   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALEFACEPT; BETAMETHASONE DIPROPIONATE; CALCIPOTRIOL; CALCIPOTRIOL HYDRATE; DITHRANOL; METHOTREXATE; PREDNISONE; STEROID; TAR; TAZAROTENE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DERMATITIS; DISEASE SEVERITY; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; FEMALE; FOLLOW UP; FUNCTIONAL DISEASE; HEADACHE; HUMAN; INJECTION SITE CONTUSION; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE REACTION; MALE; PAIN; PHARYNGITIS; PHOTOTHERAPY; PRIORITY JOURNAL; PRURITUS; PSORIASIS VULGARIS; PUSTULOSIS PALMOPLANTARIS; PUVA; REMISSION; RESPIRATORY TRACT INFECTION; SINUSITIS; TREATMENT OUTCOME; ULTRAVIOLET B RADIATION; UNSPECIFIED SIDE EFFECT; VERRUCA VULGARIS;

CHRONIC DISEASE; DERMATOLOGIC AGENTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; INJECTIONS, INTRAMUSCULAR; MALE; MIDDLE AGED; PILOT PROJECTS; PSORIASIS; RECOMBINANT FUSION PROTEINS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 37549052117     PISSN: 12034754     EISSN: None     Source Type: Journal    
DOI: 10.2310/7750.2007.00036     Document Type: Article

References (13)

1. Hellgren L, Mobacken H. Pustulosis palmaris et plantaris. Prevalence, clinical observations and prognosis. Acta Derm Venereol 1971;51:284-8.
2. Horgforsen E. Palmoplantar pustulosis. Pathogenetic studies with special reference to the role of nicotine. Acta Univs Ups 2001; 1-56.
3. Enfors W, Molin L. Pustulosis palmaris et plantaris. Acta Derm Venereol 1971;51:289-94.
4. Mengesha YM, Bennett ML. Pustular skin disorders. Diagnosis and treatment. Am J Clin Dermatol 2002;3:389-400.
5. Anttila HS, Reitamo S, Erkko P, et al. Interleukin-8 immunoreactivity in the skin of healthy subjects and patients with palmoplantar pustulosis and psoriasis. J Invest Dermatol 1992;98: 96-101.
6. Sanders ME, Makgoba MW, Sharrow SO, et al. Human memory T lymphocytes express increased levels of three cell adhesion molecules (LFA-3, CD2, and LFA-1) and three other molecules (UCHL1, CDw29, and Pgp-1) and have enhanced IFN-gamma production. J Immunol 1988;140:1401.
7. Gordon KB, Langley RG. Remittive effects of intramuscular alefacept in psoriasis. J Drugs Dermatol 2003;2:624-8.
8. Bhushan M, Burden AD, McElhone K, et al. Oral liarozole in the treatment of palmoplantar pustular psoriasis: a randomized, double-blind, placebo-controlled study. Br J Dermatol 2001;145: 546-53.
9. Yeung-Yue KA, Aronson PJ, Murakawa GJ. Clinical improvement of palmoplantar pustular psoriasis with alefacept. Poster presentation at the 63rd annual meeting of the American Academy of Dermatology; 2005 Feb 18-22; New Orleans, LA.
10. Fretzin SA, Davies KW. Efficacy and safety of efalizumab for patients with palmoplantar pustulosis. J Am Acad Dermatol 2005; 52 Suppl:2745.
11. Vitéz L, Wozel G. Severe palmoplantar pustular psoriasis: responsiveness to efalizumab in a treatment-resistant patient. In: Medimond International Proceedings of the 15th EADV Congress Rhodes (Greece), Oct 4-8, 2006. p. 779-83.
12. Dasgeb B, Holzman G, Phillips TJ. An extended 16-week course of alefacept in conjunction with reduced T-cell monitoring for the treatment of chronic plaque psoriasis. Poster presentation at the 63rd annual meeting of the American Academy of Dermatology; 2005 Feb 18-22; New Orleans, LA.
13. Asumalahti K, Ameen M, Suomela S, et al. Genetic analysis of PSORS1 distinguishes guttate psoriasis and palmoplantar pustulosis. J Invest Dermatol 2003;120:627-32.